Koru Medical reports Q2 EPS (5c), consensus (6c)

Reports Q2 revenue $6.9M, consensus $7.22M. “I am pleased with our second quarter progress, as our growth exceeded the overall SCIg market in both the U.S. and Internationally,” said Linda Tharby, KORU Medical’s President and CEO. “The foundation of our business remains sound, and we are diligently focused on delivering above-market revenue performance, advancing our portfolio with our innovation efforts, and increasing the number of drugs on our Freedom Infusion System. We are excited to welcome Tom Adams as our CFO and look forward to his continued leadership contributions. We remain committed and on track to attain our Vision 2026 strategic goals, and deliver added value to patients, customers and shareholders.”